Clinical Trial

An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-311 (NCT07179380).
Protocol Amendment History 2 changes
critical Recruitment opened 2026-08-14
notable Trial sites expanded: 0 -> 9 locations 2026-08-14
Trial Details
NCT Number NCT07234032
Lead Sponsor Insmed Incorporated
Conditions Pulmonary Hypertension, Interstitial Lung Disease
Enrollment 344 participants
Start Date 2026-07-20
Primary Completion 2031-01-22 (estimated)
Study Completion 2031-01-22 (estimated)
Updated on ClinicalTrials.gov 2026-08-13